The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer

被引：103

作者：

Gomez, Carmen E. ^{[1
]}

Najera, Jose L. ^{[1
]}

Krupa, Magdalena ^{[1
]}

Esteban, Mariano ^{[1
]}

机构：

[1] Ciudad Univ Catablanco, CSIC, Ctr Nacl Biotecnol, Dept Mol & Cell Biol, Madrid 28049, Spain

来源：

CURRENT GENE THERAPY | 2008年 / 8卷 / 02期

关键词：

D O I：

10.2174/156652308784049363

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Recombinants based on poxviruses have been used extensively as gene delivery systems to study many biological functions of foreign genes and as vaccines against many pathogens, particularly in the veterinary field. Based on safety record, efficient expression and ability to trigger specific immune responses, two of the most promising poxvirus vectors for human use are the attenuated modified vaccinia virus Ankara ( MVA) and the Copenhagen derived NYVAC strains. Because of the scientific and clinical interest in these two vectors, here we review their biological characteristics, with emphasis on virus-host cell interactions, viral immunomodulators, gene expression profiling, virus distribution in animals, and application as vaccines against different pathogens and tumors.

引用

页码：97 / 120

页数：24

共 224 条

[21] Analysis of HLA expression in human tumor tissues [J].

Cabrera, T ;

López-Nevot, MA ;

Gaforio, JJ ;

Ruiz-Cabello, F ;

Garrido, F .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2003, 52 (01) :1-9

[22]

Cao A, 2007, J CLIN ONCOL, V25

[23] Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line [J].

Carroll, MW ;

Moss, B .

VIROLOGY, 1997, 238 (02) :198-211

[24]

CARROLL MW, 2000, CANC VACCINES IMMUNO, P47

[25] Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers [J].

Cebere, I ;

Dorrell, L ;

McShane, H ;

Simmons, A ;

McCormack, S ;

Schmidt, C ;

Smith, C ;

Brooks, M ;

Roberts, JE ;

Darwin, SC ;

Fast, PE ;

Conlon, C ;

Rowland-Jones, S ;

McMichael, AJ ;

Hanke, T .

VACCINE, 2006, 24 (04) :417-425

[26] Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus ankara and vaccinia virus [J].

Chahroudi, Ann ;

Garber, David A. ;

ReeveS, Patrick ;

Liu, Luzheng ;

Kalman, Daniel ;

Feinberg, Mark B. .

JOURNAL OF VIROLOGY, 2006, 80 (17) :8469-8481

[27] Vaccinia virus strain Western Reserve protein B14 is an intracellular virulence factor [J].

Chen, RAJ ;

Jacobs, N ;

Smith, GL .

JOURNAL OF GENERAL VIROLOGY, 2006, 87 :1451-1458

[28] Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region [J].

Chen, ZW ;

Zhang, LQ ;

Qin, CA ;

Ba, L ;

Yi, CE ;

Zhang, FW ;

Wei, Q ;

He, T ;

Yu, WJ ;

Yu, J ;

Gao, H ;

Tu, XM ;

Gettie, A ;

Farzan, M ;

Yuen, KY ;

Ho, DD .

JOURNAL OF VIROLOGY, 2005, 79 (05) :2678-2688

[29]

COLLIER L. H., 1955, JOUR HYG, V53, P76

[30] Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein [J].

Cooray, Samantha ;

Bahar, Mohammad W. ;

Abrescia, Nicola G. A. ;

McVey, Colin E. ;

Bartlett, Nathan W. ;

Chen, Ron A. -J. ;

Stuart, David I. ;

Grimes, Jonathan M. ;

Smith, Geoffrey L. .

JOURNAL OF GENERAL VIROLOGY, 2007, 88 :1656-1666

← 1 2 3 4 5 6 7 8 9 10 →